Board of Directors

Dr Edward Littler

Dr Eddy Littler was COO at ReViral, a UK-based biotechnology company developing therapies for respiratory syncytial virus by developing novel first-in-class medicines. In 2018 Eddy led the fundraising of $55million Series B investment for ReViral. Before this, he was CEO at Domainex where his main focus was on investor relations, generation and delivery of the business plan and building strategic alliances; he also led a fundraising round of $5m in 2008. He has also held senior positions in Medivir, GlaxoWellcome and Wellcome Research Laboratories and has been responsible for the development of several key medicines to patients including Simeprivir for hepatitis C virus.


Baroness Professor Susan Greenfield, CBE
CEO and Founder

Baroness Greenfield, Founder and CEO of Neuro-Bio Ltd is a neuroscientist and has published over 200 papers in peer-reviewed journals over the course of her 40 year career, based mainly at Oxford University. She holds 32 honorary degrees from UK and foreign universities, has received numerous honours including the Legion d’Honneur from the French Government, an Honorary Fellowship from the Royal College of Physicians, The American Academy of Achievement Golden Plate Award, and The Australian Medical Research Society Medal. She is also a Fellow of the Royal Society of Edinburgh.


Mr David Fuente
Investor Director

Dave is the former chairman and CEO of Office Depot and former president of Sherwin-Williams Paint Stores. In addition to his role as Chairman Emeritus of SSA & Company, he is a Senior Advisor at Peter J. Solomon Company. He formerly served on the boards of Office Depot, Ryder Transportation, Dicks Sporting Good and others. Dave was appointed on the board by Kairos Ventures as an Investor Director for Neuro-Bio.


Mr Nick Stephens
Non-Executive Director

Nick is Executive Chair of The RSA Group, a global leader in Life Sciences Executive Search and Executive Interims. Serving biotech, pharma, medical devices, diagnostic, and academic medical research markets. He has been a Director of The RSA Group since 1986, joined the business full-time in 1995 and took the helm in 2000. Nick also serves as an Independent Non-Executive Director of an investment company focusing on cannabinoid and Internet-of-Things businesses; an early stage biotech company with a proprietary platform in oncology, anti-infectives and diagnostics, an IT business specializing in healthcare, travel and cybersecurity and an advanced AgriTech business.


Dr Peter Alff
Non-Executive Director

Peter works as part of the Kairos Ventures Team as an Executive in Residence, his role is to provide efficient and effective communication of technical and scientific aspects of Neuro-Bio business to Kairos representatives, including the delivery of milestones. Peter supports the business and technological engagements as directed by Neuro-Bio including assisting in: identifying additional funding for research and development with a focus on sources based in the UK, sourcing appropriate partners and R&D resources based in the US and to provide consulation on the overall strategic direction for product development and market engagement and represent Neuro-Bio at scientific and business conferences in the US.